TetraLogic Pharmaceuticals, which is developing small molecule therapeutics for the treatment of cancer, filed on Friday with the SEC to raise up to $104 million in an initial public offering. The Malvern, PA-based company, which was founded in 2001, plans to list on the NASDAQ under the symbol TLOG. TetraLogic Pharmaceuticals initially filed confidentially on September 16, 2013. The bookrunners were not disclosed in the initial prospectus. No pricing terms were disclosed.
